| |
Figure 6. Knockdowns of Xtbx6 or pMesogenin1 and 2 cause somite malformation and ventral body wall muscle hypoplasia. Representative embryos injected with Xtbx6 5mis-MO (25 ng) (A, B), Xtbx6 exint-MO (25 ng) (C-H), pMsgn MO (50 ng) (I, J), or pMesogenin1-EnR and pMesogenin2-EnR (100 pg each) (K, L). In A-L, the uninjected sides are on the left (A, C, E, G, I, K) and injected sides on the right (B, D, F, H, J, L). In some cases, images are flipped horizontally to facilitate comparison. A-D, I-L: Immunohistochemistry with the 12/101 antibody at stage 41. E-H: Analysis of expression patterns of XmyoD (E, F) and Xmyf-5 (G, H) at stage 32 by whole-mount in situ hybridization. Arrows indicate the expression of Xmyf-5 in hypaxial muscle cells. M, N: The expression of NCAM was not detectably changed in Xtbx6 exint-MO (50 ng)-injected embryos at stage 30, revealed by 4d antibody staining. |
